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ABSTRACT
Introduction Congenital anomalies are the fifth leading
cause of death in children <5 years of age globally,
contributing an estimated half a million deaths per year.
Very limited literature exists from low and middle income
countries (LMICs) where most of these deaths occur. The
Global PaedSurg Research Collaboration aims to undertake
the first multicentre, international, prospective cohort study
of a selection of common congenital anomalies comparing
management and outcomes between low, middle and high
income countries (HICs) globally.
Methods and analysis The Global PaedSurg Research
Collaboration consists of surgeons, paediatricians,
anaesthetists and allied healthcare professionals involved
in the surgical care of children globally. Collaborators will
prospectively collect observational data on consecutive
patients presenting for the first time, with one of seven
common congenital anomalies (oesophageal atresia,
congenital diaphragmatic hernia, intestinal atresia,
gastroschisis, exomphalos, anorectal malformation and
Hirschsprung's disease).
Patient recruitment will be for a minimum of 1 month
from October 2018 to April 2019 with a 30-day postprimary intervention follow-up period. Anonymous data
will be collected on patient demographics, clinical status,
interventions and outcomes using REDCap. Collaborators
will complete a survey regarding the resources and
facilities for neonatal and paediatric surgery at their
centre.
The primary outcome is all-cause in-hospital mortality.
Secondary outcomes include the occurrence of postoperative complications. Chi-squared analysis will be used
to compare mortality between LMICs and HICs. Multilevel,
multivariate logistic regression analysis will be undertaken
to identify patient-level and hospital-level factors affecting
outcomes with adjustment for confounding factors.
Ethics and dissemination At the host centre, this study
is classified as an audit not requiring ethical approval.
All participating collaborators have gained local approval
in accordance with their institutional ethical regulations.
Collaborators will be encouraged to present the results
locally, nationally and internationally. The results will be
submitted for open access publication in a peer reviewed
journal.
Trial registration number NCT03666767

Strengths and limitations of this study
►► This will be the first large-series, geographically

comprehensive, multicentre, international, prospective cohort study to define the management
and outcomes of a selection of common congenital
anomalies in low, middle and high income countries
across the globe.
►► The collaborative approach for this study allows a
large series of high-quality data to be collected in a
timely manner without overburdening high-volume,
low-resource centres.
►► The seven study conditions constitute a selection of
the most common life-threatening congenital anomalies requiring emergency surgical care in the neonatal period (box 1).
►► We recognise that some children may not reach a
facility capable of providing acute paediatric surgical care and hence the results obtained may be an
underestimation of true morbidity and mortality, especially in low and middle income countries.
►► The number of variables being collected per patient
has been limited to those known to have the greatest impact on outcomes to optimise the feasibility of
the study; follow-up is limited to 30 days post-primary intervention.

Introduction
In 2015, the Global Burden of Disease study
concluded congenital anomalies (also known
as congenital malformations, congenital
abnormalities or birth defects) to be the fifth
leading cause of death in children <5 years of
age globally.1 This equates to approximately
half a million deaths from congenital anomalies each year, 97% of which occur in low and
middle income countries (LMICs). Indeed,
this is likely to be an underestimation of the
actual number of deaths due to underdiagnosis of neonates with congenital anomalies
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Box 1

Congenital anomalies in the Global PaedSurg Study

►► Oesophageal atresia ± tracheo-oesophageal fistula
►► Congenital diaphragmatic hernia
►► Intestinal atresia
►► Gastroschisis
►► Exomphalos
►► Anorectal malformation
►► Hirschsprung’s disease

who die in the community and a lack of death certification in many LMICs.2 Not only is the mortality rate
higher in LMICs, but the prevalence is also higher due
to micronutrient deficiencies, infections and teratogens
during pregnancy resulting in more cases and a lack of
antenatal diagnosis prohibiting terminations.3 4 There is
limited research and a lack of congenital anomaly registries in LMICs, and hence they have received very little
global attention.5
The conditions forming the focus of this study (box 1)
constitute a selection of the most common life-threatening congenital anomalies during the neonatal period,
which involve the gastrointestinal tract. They each have
an incidence of 1/2000 to 1/5000, they collectively form
up to 40% of emergency neonatal surgery and associated mortality can be in excess of 50% in many LMICs.6–9
Disparities in outcomes globally can be stark; for example,
the mortality from gastroschisis is 75%–100% in many
LMICs compared with 4% or less in high income countries (HICs).10–12 Reasons for poor outcomes include a
lack of antenatal diagnosis, delayed presentation, limited
neonatal transport and in-hospital resources, a dearth of
trained support personnel and a lack of intensive care
and parenteral nutrition for neonates.9 13 14 In Uganda,
it was calculated that only 3.5% of the need for neonatal
surgery was met by the healthcare system.8
In 2010, the World Health Assembly passed a resolution recommending ‘prevention whenever possible, to
implement screening programmes and to provide care
and ongoing support to children with birth defects and
their families’.2 Prevention is paramount; however, this
is not yet possible for many congenital anomalies and
hence a focus on improving postnatal care and outcomes
is vital. The Sustainable Development Goal 3.2 aims to
end preventable deaths of newborns and children under
the age of 5 years by 2030.6 15 16 With one-third of infant
deaths being attributed to congenital anomalies, clearly,
this will not be achievable without an accelerated effort
towards the provision of surgical care for children. It is
estimated that two-thirds of deaths and disability from
congenital anomalies can be avoided with the provision
of neonatal and paediatric surgical care.6 Indeed, studies
have demonstrated such provision can be highly cost-effective in terms of disability-adjusted life-years saved.5
Yet, neonatal and paediatric surgical care remains a low
priority on the global health agenda.5
2

A shift is needed to focus on the provision of surgical
care for children within National Health Plans and
International Organisations and to elevate congenital
anomalies on the global health agenda. This large-scale,
geographically comprehensive, multicentre prospective
cohort study aims to define the current management and
outcomes of a selection of common congenital anomalies
globally and identify factors affecting outcomes that can
be modified to improve care. This is vital to aid advocacy
and global health prioritisation and inform future interventional studies aimed at improving outcomes.
Aim
To undertake the first large-scale, geographically comprehensive multicentre, prospective cohort study comparing
the management and outcomes of a selection of common
congenital anomalies in low, middle and high income
countries across the globe.
Objectives
1. To compare the mortality and post-intervention complications of a selection of common congenital anomalies involving the gastrointestinal tract in LMICs and
HICs globally.
2. To identify patient-level and hospital-level factors affecting outcomes that be modified to improve care.
3. To establish a research collaboration consisting of children’s surgical care providers across the world to help
enhance research capacity and to create a platform for
ongoing collaborative research and intervention studies aimed at improving outcomes.
4. To raise awareness and provide advocacy for neonatal
and paediatric surgical care within global health prioritisation, planning, policy and funding.
Methods and analysis
Study design
This is an international, multicentre, prospective observational cohort study. The Global PaedSurg Research
Collaboration consisting of children’s surgical care
providers (collaborators) across the world was established
from November 2017 to co-ordinate the study at an institutional level and facilitate data collection. Collaborators
are free to choose one or more months between 1 October
2018 to 30 April 2019 (inclusive) to recruit consecutive
patients to the study, with a 30-day post-primary intervention follow-up period. The primary intervention must
occur within 30 days of presentation to be included in the
study. Hence, the last date for primary data collection is
29 June 2019. Following this, there will be a period of data
collection for the data validation process continuing until
the end of August 2019.
Collaborators
International collaborators will have a variety of roles
and responsibilities within the study. Local collaborators
Wright NJ. BMJ Open 2019;9:e030452. doi:10.1136/bmjopen-2019-030452
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will establish mini-teams locally, gain study approval, use
the protocol criteria to appropriately identify patients for
study inclusion, collect prospective data and upload it to
the Research Electronic Data Capture (REDCap) online
system. Each hospital will have a local study lead who will
hold overall responsibility for ensuring the data are accurate, complete and without duplications. Country-lead
collaborators will help to recruit other collaborators from
within their country and provide advice and support
regarding gaining local study approval and data collection.
They may also help with translation of the study literature
to the local language, if required. Continent and regional
leads will help to recruit country leads, provide them with
advice regarding the study and also encourage and co-ordinate presentations of the protocol at national and international meetings. Lead investigators contributed to the study
design through the provision of feedback from the pilot
studies undertaken in multiple languages. An organising
committee will help to co-ordinate all study activities and a
steering committee will provide guidance throughout.
There are a number of benefits for collaborators participating in the study. Publishing journal(s) will be asked to
make all collaborators PubMed-citable co-authors. This
is based on an equal partnership model described by the
Lancet and is used by a number of national and international collaboratives.17–21 All collaborators will be listed as
an author on resulting presentations. Collaborators will
have the opportunity to present the study locally, nationally
and internationally, initially the study protocol and later the
results. This often provides collaborators, especially those
who are junior or from LMICs, the opportunity to apply for
funding to attend, present and network at such meetings.
Participation in the study provides an easy route and insight
into clinical research, which can be further established
through participation in the 2-year Research Training
Fellowship that is running alongside the main study free of
charge for all interested collaborators.
Sample selection
Collaborator and hospital inclusion criteria
All hospitals and healthcare professionals providing
surgical care for neonates and children, presenting for
the first time, with one or more of the study conditions
can be included in the study. Collaborators should gain
permission from the senior surgeon or physician who
oversees the care of the children to be included in the
study in order to participate. There can be up to three
collaborators in a mini-team per month of data collection. One mini-team can collect data over one or more
months or several mini-teams can collect data over a
different month each. Each mini-team must contain at
least one senior surgeon or physician to oversee the data
collection process.
Patient inclusion and exclusion criteria
Any neonate, infant or child under the age of 16 years,
presenting acutely for the first time, with one or more
of the study conditions can be included in the study.
Wright NJ. BMJ Open 2019;9:e030452. doi:10.1136/bmjopen-2019-030452

Patients who have previously received surgery for their
presenting condition or those representing with a
complication of surgery are excluded. Patients presenting
electively for surgery are excluded. Children who have
received basic resuscitative care for their condition at a
different healthcare facility and are then transferred to
the study centre for their primary surgical intervention
can be included. Children who only receive resuscitative
treatment at the study centre and are then referred elsewhere for their primary surgical intervention cannot be
included since the outcome of the surgical care will not
be known and also to avoid the risk of duplicate patients
in the study. Patients who receive conservative treatment
as their primary intervention, palliative care or no care
must be included within the study to accurately reflect the
management and outcomes of all presenting cases.
If a patient presents with more than one of the study
conditions, the details of each condition that they present
acutely with can be included, but not a previously managed
condition. For example, a newborn presenting with
oesophageal atresia and anorectal malformation would
have both conditions included. A patient presenting
for the first time with Hirschsprung’s disease at several
months of age who had a duodenal atresia repaired at
birth would have the full details of the Hirschsprungs
disease included, but the duodenal atresia would simply
be noted as an associated anomaly.
Outcome measures
The primary outcome is all-cause, in-hospital mortality.
For patient’s hospitalised for >30 days following primary
intervention, a 30-day post-primary intervention mortality
rate will be used. Those who do not receive a primary
intervention, but remain alive and hospitalised at 30 days
following primary admission, will have this time point
used for recording their mortality status for the primary
outcome. Primary outcome is defined in table 1.
The secondary outcomes include complications occurring within 30 days of primary intervention:
►► Surgical-site infection.
►► Wound dehiscence.
►► Need for re-intervention.
►► Condition-specific complications.
►► Condition specific outcome variables.
►► Length of hospital stay or time from admission to
death in patients who do not survive.
►► 30-day post-primary intervention mortality.
Secondary outcomes will not be collected on patients
who do not receive a primary intervention within 30 days
of hospital admission, with the exception of length
of hospital stay or time from admission to death. Thirty-day follow-up will be undertaken within the capacity
of the collaborating team; no additional funding will be
provided.
Data collection
Generic variables relating to the patient demographics,
antenatal care, prehospital care, clinical condition, surgical
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Table 1 Generic data points
Generic questions

Answers

During which month did the patient
present to your hospital?

October, November, December, January, February, March, April.
Please select the month that the patient presented to your hospital for the first time with this congenital
anomaly. For example, if a baby was born with gastroschisis on the 29 September and presented to
your hospital on 1 October you should select October.

Has consent been provided to include Yes, No, Patient consent is not required for this study at my institution.
this patient in the study?
If no, which condition did the patient
present with?
Oesophageal atresia, Congenital diaphragmatic hernia, Intestinal atresia, Gastroschisis, Exomphalos,
Omphalocele, Anorectal malformation, Hirschsprung's Disease.
Please select all the conditions that the patient presented with. Do not select a condition which the
patient has already received surgical treatment for previously.
Demographics
Gestational age at birth

Number of weeks from the first day of the women's last menstrual cycle until birth. Round up or down
to the nearest week.

Age at presentation (in hours)

We understand this information may be difficult to obtain - please be as accurate as you can. Please
round to the nearest hour. This number may be very large for patients who have a delayed presentation
- please still enter it. For neonates born within your centre please enter 0. Enter unknown if unknown.

Gender

Male, Female, Ambiguous, Unknown.

Weight at presentation

In kilograms (kg) on the day of presentation. Please provide a value to one decimal place.

Does the patient have another
anomaly in addition to the study
condition?

Yes: Cardiovascular, Yes: Respiratory, Yes: Gastrointestinal, Yes: Neurological, Yes: Genito-urinary, Yes:
Musculoskeletal, Yes: Down syndrome, Yes: Beckwith-Wiedemann syndrome, Yes: Cystic fibrosis, Yes:
Chromosomal, Yes: Other, No.
Select all that apply. Include all anomalies diagnosed at any stage up until 30 days post-primary
intervention or 30 days following presentation for those who did not receive an intervention. If you
suspect an associated anomaly, but it has yet to be diagnosed, select 'Yes: Other'.

Distance from the patient's home to
your hospital

In kilometres (km). Please round to the nearest kilometre. Please enter 0 if born in your hospital.

Antenatal care and delivery
Antenatal ultrasound undertaken?
If the condition was diagnosed
antenatally, at what gestational age?

Yes: study condition diagnosed, Yes: problem identified but study condition not diagnosed, Yes: no
problem identified, No.
Please round up to the nearest week. If the patient has more than one study condition, please note the
gestational age at which one or more of the conditions was first diagnosed.

Mode of transport to hospital?
Ambulance, Other transport provided by the health service, Patient's own transport, Born within the
Where did the patient present from? If hospital.
other, please specify.
Home, Community Clinic, General Practice, District Hospital, Other, Unknown.
District hospital includes secondary-level healthcare, provincial hospital, general hospital, general
mission hospital or regional hospital. It has general anaesthesia and can provide general surgical care.
Type of delivery:

Vaginal (spontaneous), Vaginal (induced), Caesarean section (elective), Caesarean section (urgent/nonelective), Unknown. Vaginal delivery includes those requiring forceps and ventouse.

Clinical condition and patient care
Was the patient septic on arrival?
If yes, were appropriate antibiotics
administered?

Yes, no.
Sepsis is SIRS with a suspected or confirmed bacterial, viral or fungal cause. SIRS is a response to a
stimulus, which results in two or more of the following: temperature >38.5°C or <36°C, tachycardia*,
bradycardia* in children <1 year old, tachypnoea*, leucopenia or leucocytosis*, hyperglycaemia*, altered
mental status, hyperlactaemia*, increased central capillary refill time >2 seconds. Arrival is the time of
birth for neonates born at your hospital. *Variables are defined as values outside the normal range for
age.
Yes: within 1 hour of arrival, Yes: within the first day of arrival, No.
Appropriate antibiotics are defined as either broad spectrum covering gram negative, gram positive and
anaerobic bacteria OR antibiotics that are the standard empirical treatment for that condition according
to local guidelines OR are based on sensitivities provided by a microbiology sample.

Continued
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Table 1 Continued
Generic questions

Answers

Was the patient hypovolaemic on
arrival?
If yes, was an intravenous fluid bolus
given?
If yes, how much intravenous fluid
was given?

Yes, No. Criteria for diagnosis include at least one of the following: prolonged central capillary refill
time >2 seconds, *tachycardia, mottled skin, *reduced urine output, cyanosis, impaired consciousness,
*hypotension. *Variables are defined as values outside the normal range for age.
Yes: within 1 hour of arrival, Yes: on the first day of arrival, No.
10–20 mL/kg, >20 mL/kg.
If <10 mL/kg was given, please select 'no' for the question asking if intravenous fluid was given.

Yes, No. Defined as <36.5°C core temperature. Arrival is the time of birth for neonates born at your
Was the patient hypothermic on
arrival?
hospital.
If yes, was the patient warmed on
arrival to within a normal temperature
range?
Yes, No. Only select yes if warming was commenced within 1 hour of arrival. Arrival is the time of birth
for neonates born at your hospital.
Did the patient receive central venous
access?
If yes, did the patient acquire central
line sepsis?

Yes: umbilical catheter, Yes: peripherally inserted central catheter, Yes: percutaneously inserted central
line with ultrasound guidance, Yes: surgically placed central line (open insertion), No.
Please select all that the patient received within 30 days of primary intervention or 30 days of
presentation if no intervention was undertaken.
Yes: diagnosed clinically, Yes: confirmed on microbiology, No.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken.

Time from arrival at your hospital to
primary intervention in hours

Enter 0 if no intervention was undertaken.
Primary intervention for each condition is defined as follows. Oesophageal atresia: surgery, either
temporising or definitive, to manage the oesophageal atresia and/or tracheo-oesophageal fistula.
Congenital diaphragmatic hernia: surgery to reduce the hernia and close the defect. Intestinal atresia:
surgery, either temporising or definitive, to manage the obstruction including stoma formation and
primary anastomosis. Gastroschisis: any procedure to either cover or reduce the bowel and/or close the
defect. This includes application of a silo (regardless of whether or not they go on to require surgery).
It excludes initial covering of the bowel in a plastic covering (bag or cling film) prior to intervention.
Exomphalos: surgery or application of topical treatment to the sac in patients managed conservatively
(regardless of whether or not they go on to require surgery). Hirschsprung's disease: surgery, either
temporising or definitive, or rectal/distal bowel irrigation, laxatives or digital stimulation in patients
managed conservatively. This does not include pre-operative washouts in patients planned to have
surgery. Anorectal malformation: surgery, either temporising or definitive, or anal/fistula dilatation in
patients with a low anorectal malformation managed conservatively.

American Society of
1.Healthy person, 2. Mild systemic disease, 3. Severe systemic disease, 4. Severe systemic disease
Anesthesiologists Score at the time of that is a constant threat to life, 5. A moribund patient who is not expected to survive without the
primary intervention
operation, Not applicable — no intervention.
What type of anaesthesia was used
for the primary intervention?

General anaesthesia with endotracheal tube, General anaesthesia with laryngeal airway, Ketamine
anaesthesia, Spinal/caudal anaesthesia, Local anaesthesia only, No anaesthesia/just analgesia, No
anaesthesia/no analgesia, Not applicable: no surgery or intervention undertaken.

Who undertook the anaesthetic for
the primary intervention?

Anaesthetic doctor, Anaesthetic nurse, Medical officer, Surgeon, Other healthcare professional, No
anaesthetic undertaken.
If more than one of these personnel were present, please select the most senior.

Who undertook the primary
intervention?

Paediatric surgeon (or junior with paediatric surgeon assisting/in the room), General surgeon (or
junior with paediatric surgeon assisting/in the room), Junior doctor, medical officer or other (without a
paediatric or general surgeon assisting/in the room), Trainee surgeon (without a paediatric or general
surgeon assisting or in the room), Not applicable — no surgery or primary intervention undertaken.

Was a Surgical Safety Checklist used Yes, No: but it was available, No: it was not available, Not applicable: a conservative primary
at the time of primary intervention?
intervention was undertaken, Not applicable: no surgery or primary intervention undertaken.
Total duration of antibiotics following
primary intervention

In days (including the day of surgery and the day antibiotics were stopped. Include intravenous and oral
antibiotics).

Did the patient receive a blood
transfusion?

Yes: not cross-matched, Yes: cross-matched, No: not required, No: it was required but not available.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken.

Did the patient require ventilation?
If yes, for how long did the patient
remain on ventilation?

Yes: and it was given, Yes: but it was not available, No.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken.
Please include all types of ventilation.
In days (include all days on ventilation within 30 days of primary intervention or 30 days of presentation
if no intervention was undertaken).

Continued
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Table 1 Continued
Generic questions

Answers

Time to first enteral feed (postprimary intervention)

In days (include the day of primary intervention and the day of first enteral feed in the calculation). Enter
0 if enteral feeds were not commenced. Enter 999 if feeds were not stopped, for example, in patients
with Hirschsprung's Disease managed conservatively. Include all types of enteral feeding — oral,
nasogastric, gastrostomy and other.

Time to full enteral feeds (postprimary intervention)

In days (enter 0 if the patient died before reaching full enteral feeds or 30 if the patient had not reached
full enteral feeds at 30 days post-primary intervention or 30 days following admission in patients
who did not receive a primary intervention). Include all types of enteral feeding — oral, nasogastric,
gastrostomy and other.

Did the patient require parenteral
nutrition?
If yes, for how long did the patient
receive parenteral nutrition?

Yes and it was given, Yes and it was sometimes available but less than required, Yes but it was not
available, No.
In days. Include all days that the patient received parenteral nutrition (any volume) up until 30 days postprimary intervention or 30 days following presentation in patients who do not receive an intervention.

Outcomes
Did the patient survive to discharge?
If the patient was discharged prior,
were they still alive at 30 days
following primary intervention?
If no, cause of death?

Yes, No.
Select yes if the patient was still alive in your hospital 30 days after primary intervention or 30 days after
presentation in patients who did not receive a primary intervention.
Yes, No: not followed-up after discharge, Followed-up but not until 30 days post-primary intervention.
This can include all reliable communication with the patient/patient’s family including in person, via
telephone and other.
Sepsis, aspiration pneumonia, respiratory failure, cardiac failure, malnutrition, electrolyte disturbance,
haemorrhage, lack of intravenous access, hypoglycaemia, recurrent tracheo-oesophageal fistula,
recurrent diaphragmatic hernia, anastomotic leak, ischaemic bowel, ruptured exomphalos sac,
enterocolitis, other. If other, please specify.

Duration of hospital stay (days)

Please include the day of admission and the day of discharge in your calculation. For example, if a
patient presented on 1 October and was discharged on the 5 October, their duration of hospital stay
would be 5 days. If the patient died, please record the number of days from admission to death. Only
include the duration of the primary admission, not subsequent admissions if the patient re-presented.

Did the patient have a surgical site
infection?

Yes, No, Not applicable: no surgical wound.
This is defined as one or more of the following within 30 days of surgery: (1) purulent drainage from the
superficial or deep (fascia or muscle) incision, but not within the organ/space component of the surgical
site OR (2) at least two of: pain or tenderness, localised swelling, redness, heat, fever, AND the incision
is opened deliberately to manage infection, spontaneously dehisces or the clinician diagnoses an SSI
(negative culture swab excludes this criterion) OR (3) there is an abscess within the wound (clinically or
radiologically detected).

Did the patient have a full thickness
wound dehiscence?

Yes, No, Not applicable — no surgical wound.
This is defined as all layers of the wound opening within 30 days of surgery.

Did the patient require a further
unplanned intervention?

Yes — percutaneous intervention, Yes — surgical intervention, No, Not applicable — no primary
intervention undertaken.
Within 30 days of primary intervention. This does not include routine reduction and closure of the defect
in neonates with gastroschisis receiving a preformed silo.

Was the patient followed up at
30 days post primary surgery
or intervention to assess for
complications?

Yes: reviewed in person, Yes: via telephone consultation, Yes: via other means, Yes: still an in-patient
at 30 days, No: data are based on in-patient observations only, No: follow-up was done but prior to
30 days.

If the patient had a complication,
when was it diagnosed?

During the primary admission, As an emergency re-attender, At routine follow-up as an outpatient, Not
applicable: no complications.

What study condition does this
patient have?

Oesophageal atresia, Congenital diaphragmatic hernia, Intestinal atresia, Gastroschisis, Exomphalos/
Omphalocele, Anorectal malformation, Hirschsprung's Disease.
If the patient has presented for the first time with more than one of these conditions, please select all
that apply. If the patient presented on this occasion with one of these conditions, but previously had
another condition managed then only select the condition they are presenting with on this occasion and
enter that they have another anomaly in the demographics section above. For example, if the patient
presents at 2 months with Hirschsprung's disease, but previously had a duodenal atresia repair, please
select Hirschsprung's disease here (not intestinal atresia) and tick in the section above that they have
another gastrointestinal anomaly.

SIRS, Systemic Inflammatory Response Syndrome.
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intervention and outcomes will be collected for all patients
in the study (table 1). Specific variables will be collected for
each individual condition (online supplementary file 1).
Outcomes and variables have been chosen using
published core outcome sets and commonly collected
outcomes in systematic reviews and meta-analyses.22–37
Collaborators will enter anonymous, deidentified data
via the secure internet-based REDCap system. This will be
stored on King’s College London REDCap server.
A short survey will be completed by the local study lead
and one other collaborating consultant or registrar on the
resources and facilities available for neonatal and paediatric
surgical care at their centre (online supplementary file 2).
Data quality
To ensure high quality of data, a detailed protocol for
collaborators has been produced and published on the
study website (www.globalpaedsurg.com) in 12 languages:
English, French, Spanish, Portuguese, German, Italian,
Chinese, Arabic, Korean, Lithuanian, Turkish and
Russian. Clear and concise definitions have been provided
for all data points on the protocol, on the data collection forms and within REDCap when entering the data.
A study launch meeting was undertaken where the principal investigator presented the data collection process
in detail, demonstrated use of REDCap and answered
questions. This was recorded, circulated to all collaborators via email and placed on the website. A frequently
asked questions document has been circulated via email
and placed on the website. Two meetings were held by
the principal investigator to detail the study, data collection process and answer questions among the country
leads so they in turn can provide advice and support to
local collaborators within their country. Again this was
recorded, circulated and placed on the website.
A pilot study of the patient data collection form and
institutional survey was undertaken by lead investigators
to optimise the study design and to address any feasibility
or other barriers to effective data collection and study
completion across participating sites. The pilot study
commenced on 1 August 2018 for 30 days in English,
Spanish and French by 41 collaborator colleagues. The
data collection forms were amended following feedback
to clarify terminology, add important missing variables or
descriptions and correct any translation errors. All translated data collection forms, REDCap and study documentation have been checked and verified by a native speaker
for accuracy.
Data validation
Ten percent of collaborating centres will be selected at
random for data validation by an independent research
collaborator. The aim will be to determine the numbers
of patients eligible during the data collection period to
check if any were missed and collect a selection of data
again to cross-check for accuracy. Validating questions
have been built into the data collection tool. At least 90%
of primary and secondary outcomes must be completed
Wright NJ. BMJ Open 2019;9:e030452. doi:10.1136/bmjopen-2019-030452

for each patient. All collaborators within validating
centres will be asked to complete a brief survey regarding
their experience with data collection to identify any
potential errors and to aid with data interpretation.
Sample size calculation
A sample size calculation was undertaken using Stata/
IC V.15.0 based on Bonferroni correction for multiple
testing, assuming 80% power and an overall type 1 error
of 5%. The required sample size for each condition has
been calculated for the primary outcome of mortality in
LMICs compared with HICs and also low, middle and
high income countries separately (table 2). Mortality estimations are based on pooled data from published studies
on these conditions in low, middle and high income
countries, respectively.
Based on the patient numbers included in the previously undertaken PaedSurg Africa study, which used a
similar study design, the estimated sample sizes to detect
a significant difference between LMICs and HICs in this
study are achievable.11
Estimated study population
The mean number of cases presenting to an institution
per month for each study condition was estimated from
published studies across all income settings (table 2). On
average, most institutions caring for patients with these
conditions receive 1–2 new cases per month; each participating institution would expect approximately 7–14 new
cases in the study per month although this can vary. The
aim is to include a minimum of 365 months of data; 183
months from LMICs and 183 months from HICs. This
should ensure enough cases of exomphalos to determine
a significant difference between LMICs and HICs; fewer
months of data are required to determine significant
differences between other study conditions. An up-todate total of patient numbers within the study will be
maintained on the study website.
Data analysis
Patient and institutional data
Data will be analysed using Stata and SAS V.9.4 (Cary,
North Carolina, USA). Missing data for the covariates will be analysed to determine whether it is related
to the outcome and either complete-case analyses or
multiple imputation techniques will be used for analyses
accordingly.
Significant differences in mortality between LMICs and
HICs will be determined for each of the study conditions
using Χ2 analysis, or Fischer’s exact test if either group
contains <10 patients. World Bank classification of low,
middle and high income countries during the fiscal year
2018 will be used.38
Univariate logistic regression analyses will be conducted
between covariates and the primary outcome of mortality.
Based on the results, covariates with a p value <0.10 will
be included in the multivariate model. The final multilevel multivariate logistic model will be determined using
7
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Table 2 Estimated mortality and sample sizes for low, middle and high income countries and the mean number of cases per
month per institution globally

Mortality LIC
(%, n)

Mortality
MIC
(%, n)

Mortality
LMIC
combined
(%, n)

OA ±TOF

79.5%
(62/78)

41.8%
(623/1488)

43.7%
(685/1566)

2.7%
(6/221)

CDH

–

47.4%
(130/274)

47.4%
(130/274)

20.4%
(201/982)

IA

42.9%
(42/98)

40.0%
(97/241)

41.0%
(139/339)

Gastroschisis

83.1%
(211/254)

42.6%
(205/481)

56.6%
(416/735)

Exomphalos

25.5%
(41/161)

31.9%
(132/414)

30.1%
(173/575)

ARM

26.3%
(26/99)

17.5%
(243/1391)

18.1%
(269/1490)

3%
(14/462)

Hirschsprung’s
disease

19.1%
(33/173)

16.8%
(55/328)

17.6%
(88/501)

2.3%
(43/1897)

Condition

Sample
Mortality HIC Sample size size for
(%, n)
for LIC
MIC
34

Sample
size for
HIC

34

23

Mean no.
cases/
month/
institution (L,
M and HIC
combined)

21

1.02

63

0.54

–

–

2.9%
(12/407)

6014

6014

25

24

0.63

3.7%
(28/748)

29

29

24

15

0.85

1040

1040

196

115

0.63

460

460

90

85

1.34

5802

5802

85

79

2.21

12.7%
(40/316)

–

Sample
size for
LMIC vs
HIC (per
group)

ARM, anorectal malformation; CDH, congenital diaphragmatic hernia; HIC, high income countries; IA, intestinal atresia; LIC, low income countries;
LMIC, low and middle income countries; MIC, middle income countries; OA, oesophageal atresia; TOF, tracheo-oesophageal fistula.

stepwise backward elimination to interventions and
peri-operative factors affecting outcomes. Data will be
adjusted for confounding factors and effect modifiers.
Potential confounders include gestation age at birth,
weight, time from birth to presentation and American
Society of Anesthesiologists score at the time of primary
intervention. Potential effect modifiers include administration of peri-operative antibiotics, fluid resuscitation,
thermal control and provision of other condition-specific
neonatal care such as parenteral nutrition in neonates
with gastroschisis.
Multi-level multivariate logistic regression analysis
will also be undertaken to identify institutional factors
affecting mortality with adjustment for confounders.
P<0.05 will be deemed significant.
Data validation
A weighted kappa statistic will be used to determine the
level of agreement between the patient data in the main
study and the validation data. It will also be used to determine the level of agreement between institutional surveys
independently completed by the local study lead and one
other consultant or registrar at each participating centre.
Results will be presented as a proportion of agreement
for each variable being validated.
Patient and public involvement
CDH UK, a patient and family advisory group and charity,
provided input into the design of the study protocol and
data collection tool. Their input will be sought on the
findings and dissemination of the results.
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Ethics and dissemination
Research ethics approval
The study has been classified as an audit at the host
institution and hence did not require ethical approval.
The study fulfils the audit criteria as follows: (1) All data
collected measures current practice. The study does not
involve any changes to patient management. (2) Current
practice and outcomes in low, middle and high income
countries will be compared with published standards
in the literature. Table 2 details the current mortality
standards for each of the seven study conditions in high
income countries. (3) All the study data are routinely
collected information which should be known to the
study team without asking additional questions to the
patients/parents. (4) All data to be entered into REDCap
are entirely anonymous. (5) No individual patient,
collaborator, institution or country will be independently
identifiable in the study results. (6) All data will be stored
securely and will be governed by King’s College London
data protection team.
Research collaborators were required to gain approval
to participate in the study at their institution according to
their local ethical regulations. Data transfer agreements
were legally signed between institutions where required.
The participating institutions, type of study approval
and study approval reference numbers are detailed in
online supplementary file 3. It was not mandated for
study approvals to be translated into English. Hence,
some reference numbers are in the local scripture of the
participating country and have therefore not been incorporated into the table.
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Study dissemination
The study concept and design will be presented at international conferences in order to recruit collaborators.
Following completion, the results will be presented at
local, national and international conferences globally.
Both the promotional presentations of the study protocol
and the study results will be presented by study collaborators of all levels of training, disciplines and regions of
the world. The results will be submitted for open access
publication in a peer reviewed journal. Following publication, the full anonymous, deidentified dataset will be
made publicly available via an online repository. Collaborators will have the opportunity to undertake sub-analyses
of the data for their country (if all collaborators from that
country agree), region or continent.
Discussion
This study aims to define, for the first time, the management and outcomes of a selection of common life-threatening congenital anomalies across the globe. This will
help to raise awareness of the unacceptable disparities
in outcomes between low, middle and high income
countries and the need to focus on improving access to
quality surgical care for neonates with congenital anomalies within national health plans and global health
prioritisation. It is hoped that factors affecting mortality
and morbidity will be identified that can be modified
to improve care. Establishment of the Global PaedSurg
Research Collaboration developed during this study will
create a platform for ongoing collaborative work and
interventional studies aimed at improving outcomes in
the future.
Twitter @GlobalPaedSurg
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